Study of predictive factors for response to 177LU-PSMA in patients with metastatic castration-resistant prostate cancer DOI Creative Commons

Hugo Peslier,

Valérie Seegers,

Pierre-Alban Dufour

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 17, 2025

Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive disease with a poor prognosis and few therapeutic options. In recent years, 177Lu-PSMA, novel radioligand therapy, has shown promising results in patients who have failed conventional therapies. However, around 30% of do not respond adequately to this treatment. retrospective cohort study, we examined clinical, biological, 68Ga-PSMA PET/CT-derived factors associated treatment response. We conducted study including 63 treated at ICO Angers for progressive mCRPC following Novel Hormonal Agents taxane-based chemotherapy. The primary endpoint was early discontinuation, defined as stopping therapy or before the 4th cycle. Secondary endpoints included PSA response overall survival. A total were study. Factors discontinuation BMI < 25 kg/m2, doubling time 2 months, hemoglobin levels <10 g/dL, albumin <35 g/L, lactate dehydrogenase (LDH) >250 IU/L alkaline phosphatase (ALP) >125 IU/L. On PET/CT imaging, low SULmax, high Total Tumor Volume, PSG score also linked discontinuation. This identified several Patients health, extensive disease, PSMA expression are higher risk failure.

Language: Английский

Study of predictive factors for response to 177LU-PSMA in patients with metastatic castration-resistant prostate cancer DOI Creative Commons

Hugo Peslier,

Valérie Seegers,

Pierre-Alban Dufour

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 17, 2025

Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive disease with a poor prognosis and few therapeutic options. In recent years, 177Lu-PSMA, novel radioligand therapy, has shown promising results in patients who have failed conventional therapies. However, around 30% of do not respond adequately to this treatment. retrospective cohort study, we examined clinical, biological, 68Ga-PSMA PET/CT-derived factors associated treatment response. We conducted study including 63 treated at ICO Angers for progressive mCRPC following Novel Hormonal Agents taxane-based chemotherapy. The primary endpoint was early discontinuation, defined as stopping therapy or before the 4th cycle. Secondary endpoints included PSA response overall survival. A total were study. Factors discontinuation BMI < 25 kg/m2, doubling time 2 months, hemoglobin levels <10 g/dL, albumin <35 g/L, lactate dehydrogenase (LDH) >250 IU/L alkaline phosphatase (ALP) >125 IU/L. On PET/CT imaging, low SULmax, high Total Tumor Volume, PSG score also linked discontinuation. This identified several Patients health, extensive disease, PSMA expression are higher risk failure.

Language: Английский

Citations

0